- United States
Curis Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
Curis (NASDAQ:CRIS) Full Year 2022 Results
Key Financial Results
- Revenue: US$10.2m (down 4.6% from FY 2021).
- Net loss: US$56.7m (loss widened by 25% from FY 2021).
- US$0.61 loss per share (further deteriorated from US$0.50 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Curis EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) exceeded analyst estimates by 1.6%.
Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 16% from a week ago.
Before we wrap up, we've discovered 5 warning signs for Curis (1 is concerning!) that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Curis is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Flawless balance sheet and slightly overvalued.